Presented on 07/10/2019 by Anjala Nizam & Arshiya Adhnon,
An insightful presentation on the UAE National Cancer Registry 2014-2018 with emphasis on Breast Cancer.
The presentation begins with a brief history of how cancer epidemiology evolved, and what is the status at present. After describing the burden of the disease of cancer globally and in India, the presentation includes a brief description of Cancer causes and prevention including screening activities. It also talks about the national Cancer Registry Program, NPCDCS and NCCP.
Knowledge, Attitude and Practice toward Cervical Cancer and Cervical Cancer S...ijtsrd
BACKGROUND Invasive Cervical Cancer ICC has been identified as the second most common cause of morbidity and mortality compared to other cancers among women in Cameroon. Cervical cancer can be treated e ectively if diagnosed early. Less than half the number of participants presented with good practice.The correlation between participants’ knowledge, attitude and practice showed that there was a significant association which therefore provides sufficient evidence to reject the null hypothesis. The result obtained in this study indicates how useful it will be to establish health education programs to increase women’s awareness and knowledge about cervical cancer. Fongang Che Landis | Enow-Orock George | Njajou Omer | Ngowe Ngowe Marcelin "Knowledge, Attitude and Practice toward Cervical Cancer and Cervical Cancer Screening and Its Associated Factors among Women in the City of Bamenda, Cameroon" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-5 | Issue-4 , June 2021, URL: https://www.ijtsrd.compapers/ijtsrd43667.pdf Paper URL: https://www.ijtsrd.commedicine/other/43667/knowledge-attitude-and-practice-toward-cervical-cancer-and-cervical-cancer-screening-and-its-associated-factors-among-women-in-the-city-of-bamenda-cameroon/fongang-che-landis
In Latin America, cancer and its control present often stark contrasts—or, in the words of one expert interviewed for this study, “light and shadow”. Rapid change occurs next to stubborn stasis, and substantial progress in some areas is intermingled with still unmet, pressing needs in others.
It is also an issue with growing political salience within the region: past success in the control of communicable diseases has increased the relative profile of non-communicable ones.
This study looks in detail at both the bright spots and the ongoing gaps for Latin American governments as they wrestle with cancer and seek to provide accessible prevention and care to their populations. Its particular focus is on 12 countries in Central and South America chosen for various factors, including their size and level of economic development. These states, referred to as “study countries”, are Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Ecuador, Mexico, Panama, Paraguay, Peru and Uruguay. Together they accounted for 92% of cancer incidence and 91% of mortality in Central and South America in 2012.
The study also introduces a major tool for stakeholders seeking to understand this field: the Latin America Cancer Control Scorecard (LACCS). The LACCS relies on significant desk research to rank the 12 study countries on their performance in different areas of direct relevance to cancer-control access. In addition to the scorecard, the report also draws on its own, separate substantial research as well as 20 interviews with experts on cancer in the region and worldwide. Its key findings include the following.
The presentation begins with a brief history of how cancer epidemiology evolved, and what is the status at present. After describing the burden of the disease of cancer globally and in India, the presentation includes a brief description of Cancer causes and prevention including screening activities. It also talks about the national Cancer Registry Program, NPCDCS and NCCP.
Knowledge, Attitude and Practice toward Cervical Cancer and Cervical Cancer S...ijtsrd
BACKGROUND Invasive Cervical Cancer ICC has been identified as the second most common cause of morbidity and mortality compared to other cancers among women in Cameroon. Cervical cancer can be treated e ectively if diagnosed early. Less than half the number of participants presented with good practice.The correlation between participants’ knowledge, attitude and practice showed that there was a significant association which therefore provides sufficient evidence to reject the null hypothesis. The result obtained in this study indicates how useful it will be to establish health education programs to increase women’s awareness and knowledge about cervical cancer. Fongang Che Landis | Enow-Orock George | Njajou Omer | Ngowe Ngowe Marcelin "Knowledge, Attitude and Practice toward Cervical Cancer and Cervical Cancer Screening and Its Associated Factors among Women in the City of Bamenda, Cameroon" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-5 | Issue-4 , June 2021, URL: https://www.ijtsrd.compapers/ijtsrd43667.pdf Paper URL: https://www.ijtsrd.commedicine/other/43667/knowledge-attitude-and-practice-toward-cervical-cancer-and-cervical-cancer-screening-and-its-associated-factors-among-women-in-the-city-of-bamenda-cameroon/fongang-che-landis
In Latin America, cancer and its control present often stark contrasts—or, in the words of one expert interviewed for this study, “light and shadow”. Rapid change occurs next to stubborn stasis, and substantial progress in some areas is intermingled with still unmet, pressing needs in others.
It is also an issue with growing political salience within the region: past success in the control of communicable diseases has increased the relative profile of non-communicable ones.
This study looks in detail at both the bright spots and the ongoing gaps for Latin American governments as they wrestle with cancer and seek to provide accessible prevention and care to their populations. Its particular focus is on 12 countries in Central and South America chosen for various factors, including their size and level of economic development. These states, referred to as “study countries”, are Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Ecuador, Mexico, Panama, Paraguay, Peru and Uruguay. Together they accounted for 92% of cancer incidence and 91% of mortality in Central and South America in 2012.
The study also introduces a major tool for stakeholders seeking to understand this field: the Latin America Cancer Control Scorecard (LACCS). The LACCS relies on significant desk research to rank the 12 study countries on their performance in different areas of direct relevance to cancer-control access. In addition to the scorecard, the report also draws on its own, separate substantial research as well as 20 interviews with experts on cancer in the region and worldwide. Its key findings include the following.
Risk Reduction Strategies for Breast-Cancer Related Lymphedema in Democratic ...CrimsonPublishers-PRM
Risk Reduction Strategies for Breast-Cancer Related Lymphedema in Democratic Republic of the Congo: Narrative Review by Jacques Lukenze Tamuzi in Perceptions in Reproductive Medicine
Background: The incidence of cancers is increasing worldwide, particularly in the developing countries as shown by recent cancer stastics from the WHO. It is even anticipated that with the increase in life expentancy, consequent upon inproved standard of living and globalization, the burden of cancers will increase within this millenium. With respective to cancer of the prostate, it is the most common type of cancer in urology. In developing countries, diagnostic is done at a late stage of evolution. In Cameroon, data on prostate cancer are scanty whereas the incidence of this disease is increasing. Objective: This article is designed to describe the epidemiological features of prostate cancer at the General Hospital of Yaoundé. Patients and methods: A 4-year retrospective study of patients seen with the diagnosis of cancer at the Medical Oncology unit of the Yaoundé General Hospital between January 2012 and December 2015. The demographic pattern (age of patients, socio professional activity, marital status), clinical features (cancer diagnosis), treatment modalities and outcome were studied. Main results: Of the 7 775 patients enrolled in the Medical Oncology Service over the study period, 1.4% (n = 108) cases of prostate cancer were seen. The prevalence over the study period was 1.38% and a relatively large annual growth of cases with an annual average of 27 cases was noted. The average age of patients was 67.82 years with a range of 34-83 years. The commonest presenting symptoms were the urinary frequency (54.63%) whereas the least common were fatigue (05.5%) and straining (03.70%). PSA was obtained in 49 patients, representing about 45.4% of all patients. Only 14 (01.26%) had biopsy reports. Conclusion: Prostate cancer is a major problem facing the aging male, and inadequate facilities make early detection difficult. Therefore, treatment is mainly palliative because of late diagnosis.
A new research paper published by Dr. Suheil Simaan and Dr. Feras Al JerfCancer Care Specilties
A new research paper published by Dr. Suheil Simaan and Dr. Feras Al Jerf in the International Journal of Cancer and Treatment under the leadership of the oncology team at Al Zahra Oncology Center in Dubai.
cancer in india, cancer trends, trends in cancer in india, economics of tobacco, tobacco economics in india, cancer demographics, cancer demographics in india, tobacco consumption in india, tobacco related cancer deaths, tobacco related cancers, population based cancer registry statistics, comparison of cancer trends in india 1994 vs 2004 vs 2011,
The number of cancer cases in Canada are projected to increase this year, largely due to the aging population there, according to new research. Here’s more:
Overall trends: An estimated 225,800 new cancer cases and 83,300 cancer deaths are expected in Canada this year — those figures for 2019 were around 220,000 and 82,000.
Specific cancers: Lung cancer is projected to account for more than a quarter of all cancer deaths, and more deaths than the next three leading causes - colorectal, pancreatic, and breast - combined.
Demographics: New cancer cases are expected to be 5% higher in men than women, while the number of cancer deaths are expected to be 12% higher among men. Prostate cancer will likely be the biggest killer among men, while breast cancer will be the most fatal among women.
Burden of Cervical Cancer & other HPV Related Diseases : Indian Perspectiv...Lifecare Centre
HPV RELATED DISEASES
Human papillomavirus (HPV) infection is now a well-established cause of cervical cancer. HPV causes virtually 100% of cervical cancer cases
There is growing evidence of HPV being a relevant factor in other ANOGENITAL CANCERS (anus, vulva, vagina and penis) and head and neck cancers.
HPV is also responsible for other diseases such as recurrent juvenile respiratory papillomatosis and genital warts
Annals of Translational Medicine & Epidemiology is a peer-reviewed, open access journal published by Austin Publishers. It provides easy access to high quality Manuscripts in all related aspects of biomedical and public health research that aims to improve the health of individuals and the community by "translating" findings into diagnostic tools, medicines, procedures, policies and education and occurrences of diseases in people.
Austin Publishing Group is a successful host of more than hundred peer reviewed, open access journals in various fields of science and medicine with intent to bridge the gap between academia and research access.
Annals of Translational Medicine & Epidemiology accepts original research articles, review articles, case reports, mini reviews, rapid communication, opinions and editorials on all the related aspects of "translating" findings into diagnostic tools, medicines, procedures, policies and education and occurrences of diseases in people.
Annual Report to the Nation on the Status of Cancer,Part I .docxjack60216
Annual Report to the Nation on the Status of Cancer,
Part I: National Cancer Statistics
Kathleen A. Cronin, PhD, MPH1; Andrew J. Lake, BS2; Susan Scott, MPH 1; Recinda L. Sherman, MPH, PhD, CTR3;
Anne-Michelle Noone, MS1; Nadia Howlader, MS, PhD1; S. Jane Henley, MSPH4; Robert N. Anderson, PhD5;
Albert U. Firth, BS2; Jiemin Ma, PhD, MHS6; Betsy A. Kohler, MPH, CTR3; and Ahmedin Jemal, DVM, PhD 6
BACKGROUND: The American Cancer Society (ACS), the Centers for Disease Control and Prevention (CDC), the National Cancer
Institute (NCI), and the North American Association of Central Cancer Registries (NAACCR) collaborate to provide annual updates
on cancer occurrence and trends in the United States. METHODS: Incidence data were obtained from the CDC-funded and NCI-
funded population-based cancer registry programs and compiled by NAACCR. Data on cancer deaths were obtained from the
National Center for Health Statistics National Vital Statistics System. Trends in age-standardized incidence and death rates for all can-
cers combined and for the leading cancer types by sex, race, and ethnicity were estimated by joinpoint analysis and expressed as the
annual percent change. Stage distribution and 5-year survival by stage at diagnosis were calculated for breast cancer, colon and rec-
tum (colorectal) cancer, lung and bronchus cancer, and melanoma of the skin. RESULTS: Overall cancer incidence rates from 2008 to
2014 decreased by 2.2% per year among men but were stable among women. Overall cancer death rates from 1999 to 2015
decreased by 1.8% per year among men and by 1.4% per year among women. Among men, incidence rates during the most recent 5-
year period (2010-2014) decreased for 7 of the 17 most common cancer types, and death rates (2011-2015) decreased for 11 of the 18
most common types. Among women, incidence rates declined for 7 of the 18 most common cancers, and death rates declined for 14
of the 20 most common cancers. Death rates decreased for cancer sites, including lung and bronchus (men and women), colorectal
(men and women), female breast, and prostate. Death rates increased for cancers of the liver (men and women); pancreas (men and
women); brain and other nervous system (men and women); oral cavity and pharynx (men only); soft tissue, including heart (men
only); nonmelanoma skin (men only); and uterus. Incidence and death rates were higher among men than among women for all racial
and ethnic groups. For all cancer sites combined, black men and white women had the highest incidence rates compared with other
racial groups, and black men and black women had the highest death rates compared with other racial groups. Non-Hispanic men
and women had higher incidence and mortality rates than those of Hispanic ethnicity. Five-year survival for cases diagnosed from
2007 through 2013 ranged from 100% (stage I) to 26.5% (stage IV) for female breast cancer, from 88.1% (stage I) to 12.6% (stage IV)
for colorectal cancer, from 55.
Risk Reduction Strategies for Breast-Cancer Related Lymphedema in Democratic ...CrimsonPublishers-PRM
Risk Reduction Strategies for Breast-Cancer Related Lymphedema in Democratic Republic of the Congo: Narrative Review by Jacques Lukenze Tamuzi in Perceptions in Reproductive Medicine
Background: The incidence of cancers is increasing worldwide, particularly in the developing countries as shown by recent cancer stastics from the WHO. It is even anticipated that with the increase in life expentancy, consequent upon inproved standard of living and globalization, the burden of cancers will increase within this millenium. With respective to cancer of the prostate, it is the most common type of cancer in urology. In developing countries, diagnostic is done at a late stage of evolution. In Cameroon, data on prostate cancer are scanty whereas the incidence of this disease is increasing. Objective: This article is designed to describe the epidemiological features of prostate cancer at the General Hospital of Yaoundé. Patients and methods: A 4-year retrospective study of patients seen with the diagnosis of cancer at the Medical Oncology unit of the Yaoundé General Hospital between January 2012 and December 2015. The demographic pattern (age of patients, socio professional activity, marital status), clinical features (cancer diagnosis), treatment modalities and outcome were studied. Main results: Of the 7 775 patients enrolled in the Medical Oncology Service over the study period, 1.4% (n = 108) cases of prostate cancer were seen. The prevalence over the study period was 1.38% and a relatively large annual growth of cases with an annual average of 27 cases was noted. The average age of patients was 67.82 years with a range of 34-83 years. The commonest presenting symptoms were the urinary frequency (54.63%) whereas the least common were fatigue (05.5%) and straining (03.70%). PSA was obtained in 49 patients, representing about 45.4% of all patients. Only 14 (01.26%) had biopsy reports. Conclusion: Prostate cancer is a major problem facing the aging male, and inadequate facilities make early detection difficult. Therefore, treatment is mainly palliative because of late diagnosis.
A new research paper published by Dr. Suheil Simaan and Dr. Feras Al JerfCancer Care Specilties
A new research paper published by Dr. Suheil Simaan and Dr. Feras Al Jerf in the International Journal of Cancer and Treatment under the leadership of the oncology team at Al Zahra Oncology Center in Dubai.
cancer in india, cancer trends, trends in cancer in india, economics of tobacco, tobacco economics in india, cancer demographics, cancer demographics in india, tobacco consumption in india, tobacco related cancer deaths, tobacco related cancers, population based cancer registry statistics, comparison of cancer trends in india 1994 vs 2004 vs 2011,
The number of cancer cases in Canada are projected to increase this year, largely due to the aging population there, according to new research. Here’s more:
Overall trends: An estimated 225,800 new cancer cases and 83,300 cancer deaths are expected in Canada this year — those figures for 2019 were around 220,000 and 82,000.
Specific cancers: Lung cancer is projected to account for more than a quarter of all cancer deaths, and more deaths than the next three leading causes - colorectal, pancreatic, and breast - combined.
Demographics: New cancer cases are expected to be 5% higher in men than women, while the number of cancer deaths are expected to be 12% higher among men. Prostate cancer will likely be the biggest killer among men, while breast cancer will be the most fatal among women.
Burden of Cervical Cancer & other HPV Related Diseases : Indian Perspectiv...Lifecare Centre
HPV RELATED DISEASES
Human papillomavirus (HPV) infection is now a well-established cause of cervical cancer. HPV causes virtually 100% of cervical cancer cases
There is growing evidence of HPV being a relevant factor in other ANOGENITAL CANCERS (anus, vulva, vagina and penis) and head and neck cancers.
HPV is also responsible for other diseases such as recurrent juvenile respiratory papillomatosis and genital warts
Annals of Translational Medicine & Epidemiology is a peer-reviewed, open access journal published by Austin Publishers. It provides easy access to high quality Manuscripts in all related aspects of biomedical and public health research that aims to improve the health of individuals and the community by "translating" findings into diagnostic tools, medicines, procedures, policies and education and occurrences of diseases in people.
Austin Publishing Group is a successful host of more than hundred peer reviewed, open access journals in various fields of science and medicine with intent to bridge the gap between academia and research access.
Annals of Translational Medicine & Epidemiology accepts original research articles, review articles, case reports, mini reviews, rapid communication, opinions and editorials on all the related aspects of "translating" findings into diagnostic tools, medicines, procedures, policies and education and occurrences of diseases in people.
Annual Report to the Nation on the Status of Cancer,Part I .docxjack60216
Annual Report to the Nation on the Status of Cancer,
Part I: National Cancer Statistics
Kathleen A. Cronin, PhD, MPH1; Andrew J. Lake, BS2; Susan Scott, MPH 1; Recinda L. Sherman, MPH, PhD, CTR3;
Anne-Michelle Noone, MS1; Nadia Howlader, MS, PhD1; S. Jane Henley, MSPH4; Robert N. Anderson, PhD5;
Albert U. Firth, BS2; Jiemin Ma, PhD, MHS6; Betsy A. Kohler, MPH, CTR3; and Ahmedin Jemal, DVM, PhD 6
BACKGROUND: The American Cancer Society (ACS), the Centers for Disease Control and Prevention (CDC), the National Cancer
Institute (NCI), and the North American Association of Central Cancer Registries (NAACCR) collaborate to provide annual updates
on cancer occurrence and trends in the United States. METHODS: Incidence data were obtained from the CDC-funded and NCI-
funded population-based cancer registry programs and compiled by NAACCR. Data on cancer deaths were obtained from the
National Center for Health Statistics National Vital Statistics System. Trends in age-standardized incidence and death rates for all can-
cers combined and for the leading cancer types by sex, race, and ethnicity were estimated by joinpoint analysis and expressed as the
annual percent change. Stage distribution and 5-year survival by stage at diagnosis were calculated for breast cancer, colon and rec-
tum (colorectal) cancer, lung and bronchus cancer, and melanoma of the skin. RESULTS: Overall cancer incidence rates from 2008 to
2014 decreased by 2.2% per year among men but were stable among women. Overall cancer death rates from 1999 to 2015
decreased by 1.8% per year among men and by 1.4% per year among women. Among men, incidence rates during the most recent 5-
year period (2010-2014) decreased for 7 of the 17 most common cancer types, and death rates (2011-2015) decreased for 11 of the 18
most common types. Among women, incidence rates declined for 7 of the 18 most common cancers, and death rates declined for 14
of the 20 most common cancers. Death rates decreased for cancer sites, including lung and bronchus (men and women), colorectal
(men and women), female breast, and prostate. Death rates increased for cancers of the liver (men and women); pancreas (men and
women); brain and other nervous system (men and women); oral cavity and pharynx (men only); soft tissue, including heart (men
only); nonmelanoma skin (men only); and uterus. Incidence and death rates were higher among men than among women for all racial
and ethnic groups. For all cancer sites combined, black men and white women had the highest incidence rates compared with other
racial groups, and black men and black women had the highest death rates compared with other racial groups. Non-Hispanic men
and women had higher incidence and mortality rates than those of Hispanic ethnicity. Five-year survival for cases diagnosed from
2007 through 2013 ranged from 100% (stage I) to 26.5% (stage IV) for female breast cancer, from 88.1% (stage I) to 12.6% (stage IV)
for colorectal cancer, from 55.
Annual Report to the Nation on the Status of Cancer,Part I .docxrossskuddershamus
Annual Report to the Nation on the Status of Cancer,
Part I: National Cancer Statistics
Kathleen A. Cronin, PhD, MPH1; Andrew J. Lake, BS2; Susan Scott, MPH 1; Recinda L. Sherman, MPH, PhD, CTR3;
Anne-Michelle Noone, MS1; Nadia Howlader, MS, PhD1; S. Jane Henley, MSPH4; Robert N. Anderson, PhD5;
Albert U. Firth, BS2; Jiemin Ma, PhD, MHS6; Betsy A. Kohler, MPH, CTR3; and Ahmedin Jemal, DVM, PhD 6
BACKGROUND: The American Cancer Society (ACS), the Centers for Disease Control and Prevention (CDC), the National Cancer
Institute (NCI), and the North American Association of Central Cancer Registries (NAACCR) collaborate to provide annual updates
on cancer occurrence and trends in the United States. METHODS: Incidence data were obtained from the CDC-funded and NCI-
funded population-based cancer registry programs and compiled by NAACCR. Data on cancer deaths were obtained from the
National Center for Health Statistics National Vital Statistics System. Trends in age-standardized incidence and death rates for all can-
cers combined and for the leading cancer types by sex, race, and ethnicity were estimated by joinpoint analysis and expressed as the
annual percent change. Stage distribution and 5-year survival by stage at diagnosis were calculated for breast cancer, colon and rec-
tum (colorectal) cancer, lung and bronchus cancer, and melanoma of the skin. RESULTS: Overall cancer incidence rates from 2008 to
2014 decreased by 2.2% per year among men but were stable among women. Overall cancer death rates from 1999 to 2015
decreased by 1.8% per year among men and by 1.4% per year among women. Among men, incidence rates during the most recent 5-
year period (2010-2014) decreased for 7 of the 17 most common cancer types, and death rates (2011-2015) decreased for 11 of the 18
most common types. Among women, incidence rates declined for 7 of the 18 most common cancers, and death rates declined for 14
of the 20 most common cancers. Death rates decreased for cancer sites, including lung and bronchus (men and women), colorectal
(men and women), female breast, and prostate. Death rates increased for cancers of the liver (men and women); pancreas (men and
women); brain and other nervous system (men and women); oral cavity and pharynx (men only); soft tissue, including heart (men
only); nonmelanoma skin (men only); and uterus. Incidence and death rates were higher among men than among women for all racial
and ethnic groups. For all cancer sites combined, black men and white women had the highest incidence rates compared with other
racial groups, and black men and black women had the highest death rates compared with other racial groups. Non-Hispanic men
and women had higher incidence and mortality rates than those of Hispanic ethnicity. Five-year survival for cases diagnosed from
2007 through 2013 ranged from 100% (stage I) to 26.5% (stage IV) for female breast cancer, from 88.1% (stage I) to 12.6% (stage IV)
for colorectal cancer, from 55.
Cancer and other noncommunicable diseases (NCDs) arenowwidely recognized as a threat to global development.The latest United Nations high-level meeting on NCDs reaffirmed thisc observation and also highlighted the slow progress in meeting the 2011 Political Declarationon the Prevention and Control of Noncommunicable Diseases and the third Sustainable Development Goal. Lack of situational analyses, priority setting,and budgeting have been identified as major obstacles in achieving these goals. All of these have incommon that they require information on the local cancer epidemiology.
The Global Burden of Disease (GBD) study is uniquely poised to provide these crucial data.
Epidemiology of oral cancer, cancer registry in India,Global Initiatives,Tobacco,Tobacco cessation centre,WHO framework,National Tobacco Control Programme,Squamous cell carcinoma,Leukoplakia, Benign,Malignant,Epidemiology,World
Sharad Ghamande, MD, FACOG
Professor and Director of Gynecologic Oncology
Augusta University Cancer Center
Presentation to the Georgia Senate Women's Adequate Healthcare Study Committee
www.gacommissiononwomen.org
Cancer RegistriesObjectives• Cancer registry definition• P.docxhumphrieskalyn
Cancer Registries
Objectives
• Cancer registry definition
• Purpose of the cancer registry
• The cancer registration process
• Importance of the cancer registry
• Cancer registrars and their responsibilities
• Types of cancer registries
Summary
Cancer registries collect, store, manage, and analyze data on people with cancer. They establish and maintain a cancer incidence reporting system, serve as an information resource for cancer research, and provide information to assist public health officials and agencies. For example, physicians need cancer data to learn more about the causes of cancer to be able to detect it earlier. Cancer registry data also helps determine the approximate percentage of people who will still be alive within a certain time period from diagnosis. Cancer registrars are trained to collect accurate, complete, and timely data. There are three types of cancer registries: hospital registries, state registries, and special cancer registries.
Topics and References
The American Cancer Society offers information and statistics on all types of cancers: www.cancer.org
The National Institutes of Health (NIH) provides information on all health topics, including cancer. NIH website: www.nih.gov
NIH article on cancer costs projection for 2020: www.nih.gov/news/health/jan2011/nci-12.htm
Abstracting
Objectives
• Cancer registry abstract definition
• What information (data) is collected
• Rules that govern abstracting
• How the collected data is used
Summary
An abstract is a record that contains information about each patient from the time of diagnosis and continuing throughout his or her life. The abstract includes patient data about demographics, diagnostic studies, cancer staging, treatment, and follow-up. When they create and update abstracts, cancer registrars must follow abstracting rules set by their individual state central registries. Hospitals that are accredited through the American College of Surgeons Commission on Cancer (ACoS/CoC) also follow ACoS/CoC abstracting rules and standards. Cancer registries transmit abstract data to their state’s cancer registry and, if the facility is ACoS/CoC-accredited, to the National Cancer Data Base (NCDB).
Topics and References
Search the Internet for your state cancer registry. What agencies does it follow for coding structures and requirements?
The North American Association of Central Cancer Registries Data (NAACCR) Standards and Data
Dictionary for abstracting: www.naaccr.org/StandardsandRegistryOperations/VolumeII.aspx
The National Program of Cancer Registries (NPCR) standards for abstracting:
www.cdc.gov/cancer/npcr/standards.htm
Commission on Cancer quality of care measures: www.facs.org/cancer/qualitymeasures.html
Comparison benchmark reports and survival reports: www.facs.org/cancer/ncdb/index.html
Coding
Objectives
• Coding manuals and applications used in the registry
• The importance of standardization
Summary
Cancer registries use multiple co ...
Ca cervix epidemiology,screening and preventionDrAnkitaPatel
CA CERVIX IS PREVENTABLE AND CURABLE IF DETECTED AT EARLY STAGE .VACCINATION, PAP SMEAR AND HPV VACCINATION ARE KEY COMPONENTS FOR PREVENTION AND EARLY DETECTION.
Similar to National Cancer Registry 2014-2018 - UAE (20)
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
4. CANCER REGISTRY
(i) Different types of treatment over time
(ii) Early detection programs
Cancer registry - an organization for the storage, collection, analysis, and
interpretation of data on individuals with cancer.
It can offer data to assess effects of:
Population-based cancer registry- gathers data from numerous healthcare
providers in a defined geographic area and serves to demonstrate incidence
trends for cancer of different sites over time or between population
subdivisions
5. Cancer registry data can be used for epidemiologic studies to identify causes of
cancer, and unusual clusters of cancer cases
Information on the mortality and incidence of cancers, in addition to their
changing trends, is an important element in the planning and monitoring of
programs for:
1. Early Detection
2. Cancer Prevention
3. Treatment
6. UAE NATIONAL CANCER REGISTRY
UAE National Cancer Registry is the
population-based cancer registry for
the UAE established under the
jurisdiction of the Ministry of Health
and Prevention.
It is part of the National Diseases
Registry which helps to access
medical information while
safeguarding data confidentiality and
it comes under the auspices of the
Statistics and Research Centre
7. Provides information on cancer patterns and trends over time as well as monitors
cancer incidence in UAE.
Produces a report about the cancer incidence on an annual basis, and as incidence
data are accumulated over the years, the registry will eventually be able to produce
certain trends which would help in studying the distribution of such conditions in
different regions of the country.
UAE NATIONAL CANCER REGISTRY
8. UAE NATIONAL CANCER REGISTRY-
OBJECTIVES
1. Population-based cancer incidence data to the public in a timely and accurate manner
2. Other indicators like:
3. For Planning:
• Cancer services
• Cancer Control
The primary aim is to provide:
• Survival • Prevalence • Mortality
• Cancer Screening Program
• Cancer Research Projects
10. SOURCES OF DATA
Comprehensive cancer registration was achieved through data obtained from::
• HAAD and DHA central cancer registry
• Hospital admissions and medical records departments from all public,
private, and university hospitals all over UAE through international
classification of disease (ICD-10 and ICD-O)
• Notifications by the medical profession
• Pathology records
• Mortality data, medical treatment abroad and others.
Notifications were made mandatory since 2013.
11. METHODS OF DATA COLLECTION
There are two methods of data collection:
1. Active Method
2. Passive Method
12. REPORTABLE LIST
Cases included in the registry are:
• Cases with behaviour code 2 (Carcinoma in-situ, Intraepithelial, Non infiltrating,
Non-invasive) and 3 (Malignant, primary site) of the International Classification of
Diseases for Oncology, third Edition (ICD-O-3).
• Malignant and in-situ cases of the ICD-10
13. THE UAE POPULATION USED TO
CALCULATE RATES
In the annual report, they use the UAE population as estimated by United Nations-
Department of Economic and Affairs, population division to compute the crude
incidence rates, and mortality rates in order to describe various indicators where
‘rates’ were calculated.
14. DATA MANAGEMENT
The UAE-NCR received around 4370 cancer cases in 2014
The database had cases of multiple reporting from multiple sources.
After checking and filtering cancer data received, the data was updated and
excluded any duplicate and already registered cases.
Total number of new cancer cases registered to UAE-NCR in 2014 were 3816.
16. 3816 new cancer cases (malignant
and in-situ) were registered between
1st January and 31 December 2014.
(a crude incidence rate of 42 per
100,000.)
4707 new cancer cases were
registered between 1st January to 31st
December 2018.
CANCER INCIDENCE
17. CANCER INCIDENCE RATE- 2014
(According to Nationality)
UAE citizens- 1003 cases were
newly diagnosed with cancer
Non-UAE citizens- 2813 cases were
newly diagnosed with cancer
21. CANCER (MALIGNANT CASES) INCIDENCE RATE
(According to Gender) 2014
Crude incidence rate of invasive cancers in females = 81.99/100000 and in males = 24.63/100,000
25. MOST COMMON TYPES OF CANCER AMONG
MALE UAE POPULATION:
2014
2018
Lung cancer was the most common cancer in men worldwide (WRCF)
26. MOST COMMON TYPES OF CANCER AMONG
FEMALE UAE POPULATION:
2014
2018
Breast cancer was the most common cancer in females worldwide (WRCF)
27. FIVE MOST COMMON TYPES OF CANCERS BY
GENDER - UAE V/S USA, 2008
UAE USA
Males- Colorectum
Females- Breast
Both- Breast
Males- Prostate
Females- Breast
Both- Lung
Most Common
Type
Most Common
Type
28. GLOBAL VARIATION OF INCIDENCE OF
CANCER
The rates for the different types of cancer in UAE were found to be much lower than
many Western as well as other Gulf countries like Qatar, Bahrain, and Kuwait. This
can be attributed towards the:
• Younger age of the population
• Less exposure to a few risk factors
• Lower trend of screening
• Possible incomplete registries
29. GLOBAL VARIATION OF PREVALENCE OF
CANCER
Various countries have various types of cancers that are prevailing in their population.
This can be due to the difference in:
• Population genetics
• Exposures
• Infections
• Radiations
• Risk factors or ethnicity
31. CANCER MORTALITY- 2014
Cancer mortality has been
contributed as the third leading
cause of death in UAE after
diseases of the CVS and injuries.
In 2014, Crude mortality rate was
8.34 deaths per 100,000.
32. MORTALITY ACCORDING TO THE
PRIMARY SITES - 2014
The most common cause of cancer death worldwide - Lung (WHO)
34. BREAST CANCER
Breast cancer was found
to be the most prevalent
cancer in females in UAE
as reported in 2004.
This trend is easily visible in
the data obtained in 2014
and 2018 demonstrating the
most frequent cancer in
females is breast cancer
among UAE population.
Females in the UAE have a
tendency to develop breast
cancer at least a decade
earlier than their
counterparts in western
countries.
36. COMPARISON BETWEEN AGE-GROUP DISTRIBUTION OF
BREAST CANCER CASES (MALIGNANT & IN-SITU) IN UAE
CITIZENS AND IN NON- UAE-CITIZENS
NON-UAE CITIZEN UAE CITIZEN
37. THE DISTRIBUTION BY MORPHOLOGY-SPECIFIC BREAST
CANCER (MALIGNANT & IN-SITU) OF 819 CASES AMONG
UAE POPULATION IN THE YEAR OF 2014
38. DISTRIBUTION BY SEER STAGE AT DIAGNOSIS OF 819 BREAST
(MALIGNANT & IN-SITU) CASES AMONG UAE POPULATION
IN THE YEAR OF 2014.
SEER: The Surveillance, Epidemiology and End Results Program of the National Cancer Institute
40. CONCLUSION
• The registry describes the geographical distribution of some of the commonest cancers,
highlighting the variation in the incidence of a variety of cancer types.
• Whilst much of the variation in modifiable cancer burden is already known, this variation
poses many questions that both researchers and policy makers alike will need to fully
consider and study.
• The results of this report show crude incidence and mortality rates in UAE on a regional
and national level and clearly demonstrated the seriousness of the cancer problem in
UAE.
42. FUTURE OPPORTUNITIES & CHALLENGES
• Cancer poses a significant present and future public health challenge.
• Increased knowledge of the frequency of malignant diseases, their incidence,
distribution, and mortality is of primary significance for controlling cancer, and the
relevant figures can only be obtained through registries.
• This information is the primary resource not only for the epidemiological determinants
found through cancer research but also for evaluating and planning health services for
the diagnosis, prevention, and treatment of the diseases.
43. REFERENCES
• Cancer Incidence in United Arab Emirates annual report of the UAE - National
Cancer Registry – 2014 by Statistics and Research Center (www.mohap.gov.ae)
• The Global Cancer Observatory (Globocan) – May 2019 [International Agency for
Research on Cancer, World Health Organisation]
• https://www.khaleejtimes.com/news/uae-health/over-4500-new-cancer-cases-
in-uae-this-year
• https://www.who.int/news-room/fact-sheets/detail/cancer
• https://www.wcrf.org/dietandcancer/cancer-trends/worldwide-cancer-data